Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2014
NCT04183387
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology

Active Ingredients

Drugs in Phase 4 Trials (1)

comarum palustre (1 trial)

Drugs in Phase 2 Trials (1)

simvastatin (zocor) (1 trial)

Drugs in Other Trials (1)

diphenhydramine (benadryl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 4)

Osteoarthritis (Phase 4)

Uveitis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3